Evidence map›Paper›PMID 42317324›Full record

ArticleFrontiers in immunology2026

Immunogenetic modulation of endothelial inflammation by the LIPG -384A/C promoter variant influences COVID-19 severity.

HariOm Singh, Aishwarya Nair, Meenakshi Bhattacharya, Gaurav Tripathi, Shamama Nishat, Abdullah F AlAsmari, Nemat Ali

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

HariOm SinghBSL-4, ICMR-National Institute of Virology, Pune, India.
Aishwarya NairBSL-4, ICMR-National Institute of Virology, Pune, India.
Meenakshi BhattacharyaDepartment of Medicine, Government Medical College & Hospital, Aurangabad, India.
Gaurav TripathiTemple University Hospital, Philadelphia, PA, United States.
Shamama NishatComprehensive Cancer Centre, Wexner Medical Centre, Ohio State University, Columbus, OH, United States.
Abdullah F AlAsmariDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Nemat AliDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe COVID-19 is characterized by dysregulated host immune responses and immune-mediated endothelial injury, culminating in microvascular dysfunction and systemic inflammation. Endothelial lipase (EL), encoded by the Methods: We performed a case-control study including 151 RT-PCR-confirmed COVID-19 patients stratified according to disease severity and 152 healthy controls. Genotyping of the Results: The Conclusion: This study identifies the

Indexed as

COVID-19Endothelium, VascularInflammationLipasePromoter Regions, GeneticSARS-CoV-2AdultAgedAllelesCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedLipaseLIPG protein, humanCOVID-19EL-384A/C polymorphismendothelial lipasegenetic susceptibilityhyperferritinemiamild COVID-19

Identifiers

PMID42317324
PMCPMC13273450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.